ABSTRACT -5-Azacytidine (5-azaC), a hypomethylating agent, was examined for the effect on a highly tumorigenic murine cell line, T984-15. While 20 of 20 untreated subclones of T984-15 produced tumors when injected into BALB/c nude mice, 14 of 15 T984-15 subclones that were treated for 24 hours with 5 I-Ig 5-azaC/ml displayed suppressed tumorigenesis under identical conditions. Of the 14 clones that were suppressed, 12 were nontumorigenic and 2 showed a greatly increased latency. Chromosome analyses of 5-azaC-treated nontumorigenic clones revealed that, in contrast to untreated tumorigenic controls (median chromosome number 49-59). 9 of 10 5-azaC-treated nontumorigenic clones analyzed displayed an elevated chromosome complement (68-94 chromosomes/ceil). The increase in chromosome number occurred progressively with time, following a single 24-hour 5-azaC treatment, indicating that 5-azaC was not selecting for a subpopulation of cells with an elevated chromosome complement. The evidence that the hypomethylating agent 5-azaC can suppress a cell's tumorigenic potential and that this suppression correlates with increased chromosome number suggests that 5-azaC modulates cellular phenotypes by mechanisms that involve alterations in a cell's chromosome complement. -JNCI 1987; 78:695-700. Toward the understanding of the mechanism(s) underlying the transition of a normal cell to a neoplastic cell, various hypotheses have been proposed. The idea that cancer has a chromosomal basis and that neoplastic progression occurs via somatic mutational events is currently widely accepted (1). However, both transformation and the reversion to a non transformed phenotype can occur at high frequencies inconsistent with somatic mutation models (2-8). Boon has reported (4, 5) that cells from several diverse murine tumors revert to a nontumorigenic phenotype (tum-) in syngeneic hosts after EMS or MNNG treatment with a frequency as high as 30%. Frost et al. (6) reported similar findings; tumorigenic murine cell lines revert to a tum-phenotype with a frequency as high as 90% when treated with EMS. In addition, it appears that the frequency of transformation of normal cells following exposure to carcinogens is inversely proportional to cell density at the time of treatment (7); Mondal and Heidelberger (8) have been able to obtain transformation frequencies as high as 100% following exposure to 3-methylcholanthrene at a very low cell density.
Toward the understanding of the mechanism(s) underlying the transition of a normal cell to a neoplastic cell, various hypotheses have been proposed. The idea that cancer has a chromosomal basis and that neoplastic progression occurs via somatic mutational events is currently widely accepted (1). However, both transformation and the reversion to a non transformed phenotype can occur at high frequencies inconsistent with somatic mutation models (2) (3) (4) (5) (6) (7) (8) . Boon has reported (4, 5) that cells from several diverse murine tumors revert to a nontumorigenic phenotype (tum-) in syngeneic hosts after EMS or MNNG treatment with a frequency as high as 30%. Frost et al. (6) reported similar findings; tumorigenic murine cell lines revert to a tum-phenotype with a frequency as high as 90% when treated with EMS. In addition, it appears that the frequency of transformation of normal cells following exposure to carcinogens is inversely proportional to cell density at the time of treatment (7); Mondal and Heidelberger (8) have been able to obtain transformation frequencies as high as 100% following exposure to 3-methylcholanthrene at a very low cell density.
Recently, epigenetic mechanisms of gene control, such as DNA methylation, have been proposed to playa role in determining a cell's oncogenic potential. The appearance of tum-cells at frequencies similar to those produced by mutagens such as EMS occurs in murine adenocarcinoma cells upon treatment with the hypomethylating agent 5-azaC (9, 10). Conversely, nonmutagenic concentrations of 5-azaC can efficiently induce the same functional step in carcinogenesis as mutagenic carcinogens (11). Since Wilson and Jones (12) and others (13, 14) have reported that mutagenic alkylating agents such as EMS and MNNG can inhibit DNA methylation, it is possible that hypomethylating agents and carcinogens such as EMS act via some common mechanism(s). Thus changes in tumorigenic potential produced by carcinogen treatment may in part be the result of changes in patterns of DNA methylation.
The T984-15 cell line is a stable, differentiationdefective variant, isolated from the myogenic cell line CI7-S1-D-T984 (15). T984-15 cells no longer express their capacity for myogenic differentiation and are highly tumorigenic. We have previously reported that 5-azaC treatment of T984-15 cells can uncouple the programs for cell differentiation and tumorigenicity (16). We report here that suppression of tumorigenic potential by 5-azaC occurs in this cell line with a high frequency and that this suppression correlates with an increased chromosome number induced in the treated cells by the cytosine analogue.
MATERIALS AND METHODS
Cell and culture conditions.-The T984-15 murine cell line was clonally isolated from CI7-SI-D-T984 (15) as previously described (17). Cells were maintained in antibiotic-free Dulbecco's modified Eagle medium supplemented with 10% fetal calf serum in a humidified atmosphere containing 95% air and 5% C02. All cells
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Toward the understanding of the mechanism(s) underlying the transition of a normal cell to a neoplastic cell, various hypotheses have been proposed. The idea that cancer has a chromosomal basis and that neoplastic progression occurs via somatic mutational events is currently widely accepted (1). However, both transformation and the reversion to a non transformed phenotype can occur at high frequencies inconsistent with somatic mutation models (2-8). Boon has reported (4, 5) that cells from several diverse murine tumors revert to a nontumorigenic phenotype (tum-) in syngeneic hosts after EMS or MNNG treatment with a frequency as high as 30%. Frost et al. (6) reported similar findings; tumorigenic murine cell lines revert to a tum-phenotype with a frequency as high as 90% when treated with EMS. In addition, it appears that the frequency of transformation of normal cells following exposure to carcinogens is inversely proportional to cell density at the time of treatment (7); Mondal and Heidelberger (8) have been able to obtain transformation frequencies as high as 100% following exposure to 3-methylcholanthrene at a very low cell density.
MATERIALS AND METHODS
Cell and culture conditions.-The T984-15 murine cell line was clonally isolated from CI7-SI-D-T984 (15) as previously described (17). Cells were maintained in antibiotic-free Dulbecco's modified Eagle medium supplemented with 10% fetal calf serum in a humidified atmosphere containing 95% air and 5% C02. All cells were tested and found to be free of Mycoplasma contamination by the uridine:uracil ratio method (18).
5-AzaC treatment.-Logarithmically growing cultures (5X10 5 cells/25-cm 2 flask) of T984-15 or a subclone, T984-15 clone ND I , were treated for 24 hours with 5 p,g 5-azaC/ml, a dose previously shown to induce myogenesis and adipogenesis in these cells (16). Following treatment, the cells were washed and plated into 100-mm dishes at 100 and 500 cells/dish. At 4 weeks, individual colonies were isolated and expanded for tumorigenicity analysis. 5-AzaC-treated T984-lS clone NDI colonies were subjected to an additional round of subcloning prior to tumorigenicity analysis.
Animals.-Congenital athymic nude BALB/c male and female mice, 4-8 weeks old, homozygous for the nulnu allele were used for tumorigenicity analysis.
Tumorigenicity.-Logarithmically growing cultures were detached from the substrate by using O.S% trypsin, washed with growth medium, and resuspended in Dulbecco's modified Eagle medium without serum at a concentration of SX 10 6 cells/m!. Using a 20-g needle, we injected 0.2 ml of the cell suspension into the subcutaneous tissue of the back of each of 2 mice. Inocula that produced a progressively growing neoplasm were scored positive for tumor formation; negative animals were maintained for 6 months.
Determination of 5-meC levels.-DNA methylation levels were determined essentially as described (19). T984-15 cells were plated at 10 4 (control) or 2XlO 4 (S-azaC) cells/dish and treated for 24 hours with 0 or S p,g S-azaC/ml beginning the following day. After treatment, the media were replaced with fresh media without drug, and 48 hours later the dishes were refed with S ml media containing [6-3 H]uridine (10 p,Ci/dish). After 24 hours, the dishes were washed with phosphatebuffered saline and the cells lysed with sodium dodecyl sulfate (O.S%) in the presence of NaOH (0.3 N). The lysate was then heated for 1 hour at 6S o C, neutralized with HCI, and treated with proteinase K. Carrier salmon sperm DNA was added and the DNA was ethanol precipitated overnight. The DNA was hydrolyzed to bases at 180°C for 30 minutes in 88% formic acid in sealed ampules, and the formic acid evaporated under nitrogen gas. We resuspended the hydrolysate in 0.1 N HCI, and bases were separated by HPLC (Waters Associates, Milford, MA), using 70% 0.08 M KH2P04 (pH 2.S) per 30% 0.03 M KH2P04 (pH 2.5) with a PartasillO SCX column (30 cmX2.S mm; Alltech Associates, Inc., Arlington Heights, IL) at a flow rate of i mllminute. Fractions were collected directly into scintillation vials at 1-minute intervals, and the radioactivity was quantitated by use of liquid scintillation techniques. Standard curves were determined for adenine, thymine, guanine, cytosine, and 5-meC with detection at 280 nm. The UV absorbtion of the column eluates was simultaneously monitored at 280 nm, and the labeled bases were identified relative to the elution times of the standards. Percent 5-meC was calculated as: Percent 5-meC=5-meC/ (5-meC + cytosine).
Chromosome analysis.-Log phase cultures were in-JNCI. VOL. 78, NO. 4, APRIL 1987 cubated in the presence of 0.06 p,g Colcemid/ml for 4 hours, harvested, and centrifuged in IS-ml tubes at 1,000 rpm for 3 minutes. The growth medium was aspirated and the pellet was resuspended in 3 ml of 0.075 M KCl at 37°C for IS-20 minutes to swelJ the cells. Approximately 0.5 ml of fix (3: I of MeOH:acetic acid) was added to each tube, the cells were repelleted, the KCI was decanted, and the pellet was resuspended in ice-cold fix. The cells were refrigerated overnight, pelleted, and resuspended in fresh ice-cold fix. After a final centrifugation, the pelJet was resuspended in 0.2-0.5 ml ice-cold fix, dropped onto clean ice-cold slides, and air dried. Fifty metaphase spreads were counted for each clone analyzed.
RESULTS

5-AzaC Suppression of Tumorigenic Potential at a High Frequency
The murine cell line T984-15 is highly tumorigenic; in previous experiments, 14 of 14 subclones of this line produced tumors when injected into nude mice (17). In this series of experiments, 6 subclones of T984-15 were injected sc into nude mice at a dose of 10 6 cells. As shown in table 1 all T984-1S sub clones were tumori- a Control cells and 5-AzaC-treated cells were injected sc into the backs of nude mice at a concentration of 10 6 cells/inoculum as described in "Materials and Methods." Inocula that produced a progressively growing neoplasm were scored positive (+) for tumor formation; negative animals (0) were maintained for 6 mo.
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were tested and found to be free of Mycoplasma contamination by the uridine:uracil ratio method (18).
Determination of 5-meC levels.-DNA methylation levels were determined essentially as described (19). T984-15 cells were plated at 10 4 (control) or 2XlO 4 (S-azaC) cells/dish and treated for 24 hours with 0 or S p,g S-azaC/ml beginning the following day. After treatment, the media were replaced with fresh media without drug, and 48 hours later the dishes were refed with S ml media containing [6-3 H]uridine (10 p,Ci/dish). After 24 hours, the dishes were washed with phosphatebuffered saline and the cells lysed with sodium dodecyl sulfate (O.S%) in the presence of NaOH (0.3 N). The lysate was then heated for 1 hour at 6S o C, neutralized with HCI, and treated with proteinase K. Carrier salmon sperm DNA was added and the DNA was ethanol precipitated overnight. The DNA was hydrolyzed to bases at 180°C for 30 minutes in 88% formic acid in sealed ampules, and the formic acid evaporated under nitrogen gas. We resuspended the hydrolysate in 0.1 N HCI, and bases were separated by HPLC (Waters Associates, Milford, MA), using 70% 0.08 M KH2P04 (pH 2.S) per 30% 0.03 M KH2P04 (pH 2.5) with a PartasillO SCX column (30 cmX2.S mm; Alltech Associates, Inc., Arlington Heights, IL) at a flow rate of i mllminute. Fractions were collected directly into scintillation vials at 1-minute intervals, and the radioactivity was quantitated by use of liquid scintillation techniques. Standard curves were determined for adenine, thymine, guanine, cytosine, and 5-meC with detection at 280 nm. The UV absorbtion of the column eluates was simultaneously monitored at 280 nm, and the labeled bases were identified relative to the elution times of the standards. Percent 5-meC was calculated as: Percent 5-meC=5-meC/ cubated in the presence of 0.06 p,g Colcemid/ml for 4 hours, harvested, and centrifuged in IS-ml tubes at 1,000 rpm for 3 minutes. The growth medium was aspirated and the pellet was resuspended in 3 ml of 0.075 M KCl at 37°C for IS-20 minutes to swelJ the cells. Approximately 0.5 ml of fix (3: I of MeOH:acetic acid) was added to each tube, the cells were repelleted, the KCI was decanted, and the pellet was resuspended in ice-cold fix. The cells were refrigerated overnight, pelleted, and resuspended in fresh ice-cold fix. After a final centrifugation, the pelJet was resuspended in 0.2-0.5 ml ice-cold fix, dropped onto clean ice-cold slides, and air dried. Fifty metaphase spreads were counted for each clone analyzed.
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genic; progressively growing neoplasms appeared in inoculated animals after a latency of 1-2 months.
T984-15 cells and cells from a tumorigenic subclone of this line, T984-15 clone ND 1 , were treated with 5 f-tg 5-azaC/ml as described in "Materials and Methods." After treatment, cells were plated at clonal density; 4 weeks later 9 clones were isolated from the 5-azaCtreated T984-15 population and 6 clones were isolated from the 5-azaC-treated T984-15 clone NDI population (total = 15 clones). The 15 5-azaC-treated clones were expanded, injected sc into nude mice at a density of 10 6 cellslinoculum, and analyzed for their ability to produce tumors. As shown in table 1, of the 15 5-azaCtreated clones analyzed, 14 clones were suppressed in their tumorigenic potential: Twelve clones were nontumorigenic and 2 clones displayed an increased latency relative to tumorigenic controls. Only I of the 15 clones, 5-azaC T984-15 clone 4, remained highly tumorigenic after drug treatment. Thus, whereas T984-15 subclones produced tumors when injected into nude mice with a high tumor frequency (100%), greater than 90% of the 5-azaC-treated subclones were suppressed in their tumorforming ability.
5-AzaC Treatment Hypomethylating T984-15 DNA
The effect of drug treatment on levels of 5-meC was measured, as described in "Materials and Methods," by using 3H-Iabeled DNA extracted from T984-15 cells treated for 24 hours with 0 or 5 f-tg 5-azaC/ml. HPLC analysis indicated that, whereas untreated T984-15 cells contained 3.59±0.21 % 5-MeC, this level dropped to 2.42±0.18% in cells treated with 5-azaC. Thus under conditions in which 5-azaC treatment suppresses the tumorigenic potential of T984-15 cells, DNA methylation was reduced by 33%.
5-AzaC-lnduced Tumorigenic Suppression Correlating With Increased Chromosome Number
To understand the mechanism of 5-azaC-induced tumorigenic suppression, we compared the chromosome number of control T984-15 clones to clones that had been isolated following 5-azaC treatment. Previous studies showed no significant difference in growth rate between 5-azaC-treated clones and controls (average doubling time of treated cells=19.2±1.6 hr; untreated= 19.0±3. chromosome number of 90; greater than 94% of the cells contained more than 65 chromosomes. A total of 5 untreated tumorigenic control clones and II 5-azaC-treated clones were subjected to chromosome analysis. As shown in table 2, 6 of 6 tumorigenic clones (including 1 5-azaC-treated clone) had a median chromosome number that ranged between 46 and 59. In contrast, 9 of 10 5-azaC-treated clones that were nontumorigenic displayed an elevated chromosome number, with median chromosome numbers ranging from 68 to 94. One nontumorigenic clone, 5-azaC T984-15 clone AND 4 , however, had a median chromosome number of 53, indicating that an overall increase in chromosome number was not an absolute requirement for suppression of tumorigenic potential.
5-AzaC Inducing an Increase in Chromosome Number
Although the median chromosome number of T984-15 cells is 57, approximately 10% of the cells have a chromosome complement in excess of 65 chromosomes/ cell. Because 5-azaC is cytotoxic to T984-15 cells (treatment with 5 f-tg 5-azaC/ml reduces cloning efficiency to 12% of control), it is important to ask whether the increase in chromosome number observed following 5-azaC treatment occurred due to the elimination of those cells with a low median chromosome number resulting in a selective enrichment for cells that had a high median chromosome number prior to drug treatment. To determine whether treatment with 5-azaC genic; progressively growing neoplasms appeared in inoculated animals after a latency of 1-2 months.
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5-AzaC Inducing an Increase in Chromosome Number
Although the median chromosome number of T984-15 cells is 57, approximately 10% of the cells have a chromosome complement in excess of 65 chromosomes/ cell. Because 5-azaC is cytotoxic to T984-15 cells (treatment with 5 f-tg 5-azaC/ml reduces cloning efficiency to 12% of control), it is important to ask whether the increase in chromosome number observed following 5-azaC treatment occurred due to the elimination of those cells with a low median chromosome number resulting in a selective enrichment for cells that had a high median chromosome number prior to drug treatment. To determine whether treatment with 5-azaC selected for a component of the population with a higher chromosome complement, we compared the change in chromosome distribution of the treated cells through time. Whereas an immediate shift in chromosome number would not rule out the possibility that 5-azaC treatment had selectively enriched for cells with a higher chromosome complement, a progressive increase in chromosome number would suggest that 5-azaC had not acted as a selective agent but rather that the effect of 5-azaC was manifested after treatment and during the course of many cell divisions.
Following a 24-hour treatment with 5 p.g 5-azaC/ml, T984-15 cells were subjected to chromosome analysis Of the tumorigenic cells analyzed, including 1 5-azaCtreated clone that had remained tumorigenic, 6 of 6 had a median chromosome number between 46 and 59 chromosomes/cell. In contrast, 9 of 10 5-azaC-treated clones that were nontumorigenic had an elevated number of chromosomes; the median chromosome number of these cells ranged between 68 and 94 chromosomes/ cell.
The overall increase in chromosome number that occurred following 5-azaC treatment suggests that the suppression of tumorigenicity following drug treatment may have occurred as a secondary event resulting from a gene dosage effect that occurred in the treated cells. The 698 Walker, Matthews, and Shay selected for a component of the population with a higher chromosome complement, we compared the change in chromosome distribution of the treated cells through time. Whereas an immediate shift in chromosome number would not rule out the possibility that 5-azaC treatment had selectively enriched for cells with a higher chromosome complement, a progressive increase in chromosome number would suggest that 5-azaC had not acted as a selective agent but rather that the effect of 5-azaC was manifested after treatment and during the course of many cell divisions.
Following a 24-hour treatment with 5 p.g 5-azaC/ml, T984-15 cells were subjected to chromosome analysis 
DISCUSSION
5-AzaC treatment of the highly tumorigenic murine cell line, T984-15, results in a high-frequency suppression of the ability of these cells to produce tumors when injected into nude mice. Whereas 20 of 20 untreated clones of control T984-15 cells produced tumors, 14 of 15 5-azaC-treated clones were suppressed in their tumorforming ability. Of the 14 clones that were suppressed, 12 were nontumorigenic and 2 displayed an increased latent period. When the distribution of chromosome number was compared between tumorigenic T984-15 cells and non tumorigenic 5-azaC-treated clones, it was observed that, in general, suppression of tumorigenic potential correlated with increased chromosome number. Of the tumorigenic cells analyzed, including I 5-azaCtreated clone that had remained tumorigenic, 6 of 6 had a median chromosome number between 46 and 59 chromosomes/cell. In contrast, 9 of 10 5-azaC-treated clones that were nontumorigenic had an elevated number of chromosomes; the median chromosome number of these cells ranged between 68 and 94 chromosomes/ cell.
The overall increase in chromosome number that occurred following 5-azaC treatment suggests that the suppression of tumorigenicity following drug treatment may have occurred as a secondary event resulting from a gene dosage effect that occurred in the treated cells. The b Authors of (40) note that the differentiated cell lines described were not necessarily clonal in origin. suggesting that this line is actually composed of a mixed population of stem cells and their differentiated derivatives.
chromosome number in the suppressed clones ranged from 94 to 53. indicating that duplication of the entire chromosome complement of T984-15 was not required to suppress tumorigenicity and suggests that, although 5-azaC can induce a very marked increase in chromosome number, the balance of only a few chromosomes may be sufficient to determine tumorigenic potential. Further karyotypic analysis may be able to identify specific chromosomes involved in determining the tumorigenic phenotype in T984-15 cells. However. the fact that 5-azaC induced an overall increase in chromosome number detectable at the population level in treated T984-15 cells as well as in 9 of II treated subclones indicates that increased chromosome number as a result of 5-azaC treatment was a high-frequency event. Whether this event was due to the hypomethylating effect of 5-azaC or an as yet unknown mechanism is unclear. The effects of other hypomethylating agents on the chromosome complement of T984-15 have not been studied; although HPLC analysis indicates an immediate decrease in 5-meC levels after drug treatment, whether this overall hypomethylation persists with continued subculturing is not known.
It is interesting to speculate that high-frequency suppression of tumorigenic potential and increased chromosome number produced by 5-azaC are related to the embryonic origin of the T984-15 cell line. The embryonal carcinoma cell line C1751, from which the T984-15 was derived (17), is highly tumorigenic and contains a low chromosome complement characteristic of embryonal carcinoma cell lines (table 3) . In contrast. differentiated derivatives of C1751 as well as derivatives from other embryonal carcinoma cell lines display an elevated chromosome number and are non tumorigenic. Thus the suppression of tumorigenic potential induced by 5-azaC, which is correlated with increased chromosome number. mimics the increased chromosome number that is associated with loss of tumorigenicity in differentiated cell lines derived from embryonal carcinomas. However, suppression of tumorigenic potential in T984-15 cells by 5-azaC occurred in the absence of a concomitant induction of differentiation; only I of 14 clones whose tumorigenic potential was suppressed following 5-azaC treatment also regained the ability to differentiate myogenically (data not shown).
Several lines of evidence suggest that DNA methylation plays a role in maintaining chromosome structure.
Although 5-azaC is only weakly mutagenic in eukaryotes (20) . it has been shown in some systems to cause chromosomal aberrations such as endoreduplication (21-23) and it can affect chromosome replication patterns (24) . The concept that methylation of cytosine residues is an effective mechanism for silencing gene activity (25) has been extended to suggest a role for DNA methylation in X chromosome inactivation (26, 27) . In addition, satellite DNA, which is enriched in sequences containing methylated cytosine residues (28) (29) (30) . clusters around the centromeric regions of mitotic chromosomes; these regions have been shown to react strongly with antibodies specific for methylated DNA (30, 31) . Treatment with 5-azaC has been shown to induce distinct undercondensations in these regions of centromeric heterochromatin in human chromosomes (32) .
Because these centromeric regions function as attachment points for the mitotic apparatus, it is not unreasonable to speculate that alterations in DNA methylation levels affecting these regions may result in alterations in chromosome sorting during mitosis. If this hypothesis is correct. one might predict that treatment of cells with hypomethylating agents such as 5-azaC could affect chromosome segregation and result in the appearance of cells expressing "new" cellular phenotypes due to an altered chromosome complement. Harrison et al. (33) have shown that 5-azaC treatment of hamster CHEF cells can produce alterations in the chromosome complement of treated cells, these alterations correlating with the induction of tumorigenicity. Our results. in which 5-azaC-induced suppression of tumorigenicity was correlated with increased chromosome number. are consistent with the hypothesis that hypomethylating agents such as 5-azaC have the potential to influence cellular phenotype due to the induction of altered chromosome complements. b Authors of (40) note that the differentiated cell lines described were not necessarily clonal in origin. suggesting that this line is actually composed of a mixed population of stem cells and their differentiated derivatives.
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Because these centromeric regions function as attachment points for the mitotic apparatus, it is not unreasonable to speculate that alterations in DNA methylation levels affecting these regions may result in alterations in chromosome sorting during mitosis. If this hypothesis is correct. one might predict that treatment of cells with hypomethylating agents such as 5-azaC could affect chromosome segregation and result in the appearance of cells expressing "new" cellular phenotypes due to an altered chromosome complement. Harrison et al. (33) have shown that 5-azaC treatment of hamster CHEF cells can produce alterations in the chromosome complement of treated cells, these alterations correlating with the induction of tumorigenicity. Our results. in which 5-azaC-induced suppression of tumorigenicity was correlated with increased chromosome number. are consistent with the hypothesis that hypomethylating agents such as 5-azaC have the potential to influence cellular phenotype due to the induction of altered chromosome complements. 
